American Journal of Hypertension, published by Oxford University Press, is a leading peer-reviewed journal dedicated to the field of hypertension and cardiovascular health. With an ISSN of 0895-7061 and an E-ISSN of 1941-7225, this prestigious journal has been providing researchers and clinicians with significant advancements in hypertension research since its inception in 1954, with a continued focus on innovative studies through 2024. Ranked Q2 in Internal Medicine and positioned within the top 22% of its category according to Scopus, it is a vital resource for those involved in clinical practice and research aimed at understanding and managing hypertension. The journal disseminates pivotal findings, treatment updates, and guideline recommendations that contribute to improved patient care globally. Accessible solely through subscription, the American Journal of Hypertension is essential reading for professionals committed to enhancing cardiovascular health outcomes.

BLOOD PRESSURE is a distinguished journal published by Taylor & Francis Ltd in the field of cardiology and internal medicine, with an ISSN of 0803-7051 and E-ISSN of 1651-1999. Since its inception in 1992, it has become a vital source of research and clinical information, dedicated to advancing our understanding of blood pressure-related health issues. With a notable categorization of Q3 in Cardiology and Cardiovascular Medicine and Q2 in Internal Medicine as of 2023, this journal exemplifies a commitment to evidence-based findings that impact clinical practice and patient care. The journal facilitates a platform for original research, reviews, and case studies, aiming to bridge the gap between researchers and practitioners. Although it does not currently offer open access, BLOOD PRESSURE remains an essential resource for professionals and students alike, striving to enhance health outcomes through dedication to innovative cardiovascular research.

Turk Kardiyoloji Dernegi Arsivi-Archives of the Turkish Society of Cardiology is a prominent peer-reviewed journal dedicated to advancing the field of cardiology and cardiovascular medicine. Published by KARE PUBL, this journal has established itself as a key resource for researchers, healthcare professionals, and students since its inception in 1990. As an Open Access journal since 2017, it ensures that cutting-edge research and clinical findings are readily accessible to a global audience, thus fostering collaboration and knowledge sharing among the cardiology community. With its recent rank in the Q3 quartile for Cardiology and Cardiovascular Medicine in 2023, and a Scopus rank of #282 out of 387, the journal is positioned to enhance its influence in the cardiovascular field, offering valuable insights and promoting evidence-based practices. The journal covers a wide range of topics within cardiology and cardiovascular research, making it an essential platform for scholars aiming to contribute to the ongoing dialogue in this vital area of medicine. For those eager to stay updated with the latest research trends and clinical practices in cardiology, Turk Kardiyoloji Dernegi Arsivi represents a crucial resource.

Integrated Blood Pressure Control is a distinguished Open Access journal published by DOVE MEDICAL PRESS LTD in New Zealand, dedicated to advancing the field of cardiology and cardiovascular medicine as well as internal medicine. With its established timeline from 2009 to 2024, this journal has earned a commendable Q2 ranking in both its categories for 2023, reflecting its significant contribution to clinical research and practice. With an ISSN of 1178-7104, it provides a platform for high-quality, peer-reviewed articles that address the complexities of blood pressure management, aiming to improve patient outcomes and foster discussions among healthcare professionals. The journal's open-access model, implemented since 2008, ensures that research findings are readily available to all, promoting greater accessibility and dissemination of knowledge in this critical area of health. Researchers, professionals, and students alike are encouraged to engage with the latest findings and innovative practices published within this journal, which plays an essential role in shaping the future of blood pressure control and related medical fields.

Clinical Hypertension is a premier journal dedicated to advancing the field of hypertension and cardiovascular health, published by SpringerNature. Since its transition to an Open Access model in 2014, the journal has opened doors for researchers globally to share their findings without barriers, aiming to foster collaboration and innovation in this vital area of medicine. With a current impact factor that positions it in the Q2 quartile for both Cardiology and Cardiovascular Medicine and Internal Medicine, Clinical Hypertension is recognized for its scholarly contributions, reflected in its Scopus rankings (Rank #100/387 in Cardiology and Rank #52/167 in Internal Medicine), which place it in the top percentiles of these competitive fields. Covering a diverse range of topics within hypertension research, it serves as an essential resource for clinicians, researchers, and students alike, promising to keep its audience informed of the latest developments and breakthroughs from its inception in 2017 through to 2024.

Metabolic Syndrome and Related Disorders is an esteemed journal published by MARY ANN LIEBERT, INC, focusing on the multifaceted aspects of metabolic syndrome, including its interaction with chronic diseases such as diabetes, cardiovascular conditions, and obesity. Since its inception in 2003, this journal has established itself as a vital resource for researchers, healthcare professionals, and students dedicated to advancing knowledge in the fields of endocrinology, internal medicine, and metabolic disorders. With an impact factor reflective of its academic significance, Metabolic Syndrome and Related Disorders is recognized within the Q2 and Q3 quartiles in its respective categories, solidifying its reputation among scientific and clinical communities. Although it does not currently offer open access options, the journal remains committed to disseminating high-quality research and reviews that foster innovative solutions and improve patient outcomes. The journal's gradual convergence towards 2024 presents an exciting opportunity for continued exploration and dialogue about metabolic-related health challenges.

Asian Biomedicine, published by WALTER DE GRUYTER GMBH, serves as a crucial platform for disseminating pioneering research in the field of biomedical sciences. Established in 2008, this journal has carved its niche in the landscape of academic publishing, concentrating on a diverse array of topics within biochemistry, genetics, and molecular biology, as well as medicine. Though it currently holds a Q4 ranking in its category, it is dedicated to fostering academic discussions and advancing knowledge among researchers, professionals, and students alike. While the journal features a variety of access options, it is committed to ensuring that its content remains relevant and impactful, with an emphasis on the latest developments and research trends. The editorial board encourages submissions that address pressing biomedical issues, thus empowering contributors to engage meaningfully with the scientific community. With a broad international scope and a focus on quality, Asian Biomedicine is poised to play an increasingly important role in the advancement of biomedical research in Asia and beyond.

JOURNAL OF HUMAN HYPERTENSION, a prominent publication in the field of internal medicine, is dedicated to advancing the understanding of hypertension and its implications for human health. Published by SPRINGERNATURE in the United Kingdom, this esteemed journal has been a vital resource for researchers and clinicians since its inception in 1987, with a continuous commitment to disseminating high-quality, peer-reviewed research. With an impressive Q2 category rank in Internal Medicine and a Scopus rank of 53 out of 167, it occupies a crucial position within the academic community, reaching a 68th percentile ranking that underscores its significance. The journal aims to provide a platform for innovative studies and reviews, fostering knowledge that bridges basic science, clinical practice, and public health. Although it does not currently offer open access, it remains accessible through institutional subscriptions, ensuring that vital information about hypertension is available to a broad spectrum of healthcare professionals and researchers. Explore the critical findings and groundbreaking research published in the JOURNAL OF HUMAN HYPERTENSION to stay at the forefront of hypertension studies.

Journal of Atherosclerosis and Thrombosis is a leading academic publication dedicated to advancing research in the fields of cardiovascular medicine, biochemistry, and internal medicine. Published by the Japan Atherosclerosis Society, this esteemed journal operates from its headquarters in Tokyo, Japan, and has been a vital resource in its area since its inception in 1994. With its robust impact in Cardiology and Cardiovascular Medicine, ranking in the top quartile (Q1) as of 2023, and a commendable standing in Internal Medicine and Biochemistry, the journal fosters an environment of innovation and discovery, showcasing significant studies and advancements that shape clinical practices and therapeutic approaches. Though not an open-access publication, it offers a wealth of insights to researchers, professionals, and students seeking to deepen their understanding of atherosclerosis and thrombosis. By continually featuring high-quality articles, the Journal of Atherosclerosis and Thrombosis plays an essential role in bridging the gap between research and practice, facilitating critical conversations that influence the future of cardiovascular health.

JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM, published by SAGE PUBLICATIONS INC, stands as a vital resource in the fields of Endocrinology and Internal Medicine. With an impressive open access model established in 2014, this journal facilitates broad dissemination of high-quality research that explores the complex mechanisms and clinical implications of the renin-angiotensin-aldosterone system (RAAS). Currently, it is recognized within the 2023 Category Quartiles as Q3 in Endocrinology and Q2 in Internal Medicine, reflecting its significant impact on the scientific community. The journal ranks in the 75th percentile for Internal Medicine and the 57th percentile in Endocrinology according to Scopus, indicating its strong contributions to these disciplines. Covering a rich history from its inception in 2000 to the present, the journal aims to bridge the gap between basic research and clinical practice, thereby enhancing the understanding and treatment of conditions influenced by RAAS. The continuous publication of innovative research makes it an essential reference for researchers, healthcare professionals, and students engaged in these dynamic fields.